Apyx medical corporation reports preliminary fourth quarter and full year 2021 revenue results

Clearwater, fla.--(business wire)--apyx medical corporation (nasdaq:apyx) (the “company”), a maker of medical devices and supplies and the developer of helium plasma technology, marketed and sold as renuvion® in the cosmetic surgery market and j-plasma® in the hospital surgical market, today reported preliminary revenue results for the fourth quarter and full year ended december 31, 2021. preliminary fourth quarter 2021 revenue summary: total revenue in a range of $16.3 to $16.8 million, repres
APYX Ratings Summary
APYX Quant Ranking